-
Arrowhead CEO Comments on $4.5M Alliance Between Unidym and Samsung Electronics
Thursday, December 9, 2010 - 9:40am | 643Arrowhead Research Corporation's (NASDAQ: ARWR) President and Chief Executive Officer today issued the following open letter to the Company's shareholders: Dear Shareholders: Yesterday Unidym announced that it has entered into intellectual property cooperation and license agreements with...
-
Auriga Sees Strong Upside In Illumina
Thursday, December 9, 2010 - 9:33am | 147Auriga has a Buy rating and a $75 price target on Illumina Inc. (NASDAQ: ILMN). In a note sent to investors Auriga writes, "Illumina's (ILMN, Buy) product portfolio should enable it to maintain and even expand its market-leading position. In turn, a number of factors – limited penetration (NGS...
-
Luminex, One Lambda Renew Tie - Analyst Blog
Wednesday, December 8, 2010 - 6:00pm | 579Luminex Corporation (LMNX), a developer of biological testing technologies, has renewed its long-standing strategic collaboration with leading transplant diagnostic products maker One Lambda Inc. The partnership, which began in 2000, focuses on developing technologies for human leukocyte antigen...
-
Luminex, One Lambda Renew Tie - Analyst Blog
Wednesday, December 8, 2010 - 5:41pm | 579Luminex Corporation (LMNX), a developer of biological testing technologies, has renewed its long-standing strategic collaboration with leading transplant diagnostic products maker One Lambda Inc. The partnership, which began in 2000, focuses on developing technologies for human leukocyte antigen...
-
Leerink Swann & Co Upgrades BIO To Outperform
Wednesday, December 8, 2010 - 9:09am | 43Analysts at Leerink Swann & Co upgrade Bio-Rad Laboratories Inc (NYSE: BIO) from "market perform" to "outperform." BIO's shares gained 1.24% to close at $97.72 yesterday. More Analyst Ratings here
-
Luminex and One Lambda Renew 10-Year Strategic Partnership
Tuesday, December 7, 2010 - 5:36pm | 70Luminex Corporation (Nasdaq: LMNX) and One Lambda, Inc. have agreed to a long-term renewal of their 10-year strategic partnership aimed at developing platforms and technologies for human leukocyte antigen typing and antibody screening for the organ transplantation market. Begun in 2000, their...
-
Bio-Rad To Refinance Debt
Tuesday, December 7, 2010 - 10:23am | 123Jefferies & Co has published a research report on Bio-Rad Laboratories (NYSE: BIO) after the company shows its signs of refinancing debt and raising forecasts. In the report, Jefferies writes "BIO will redeem all of its 7.5% ($225M) and 6.125% senior subordinate notes ($200M) through the...
-
Options Brief: Medivation (MDVN)
Monday, December 6, 2010 - 3:45pm | 109Shares of Medivation (NASDAQ: MDVN) are higher on the session by 3.75%, trading at $11.63. Overall put volume is now running at 25.93x the daily average, with 8% of all puts traded being purchases on the offer. 1,115 contracts have traded on the session so far. Medivation, Inc. is a...
-
Setback for Valeant Epilepsy Drug - Analyst Blog
Friday, December 3, 2010 - 7:00pm | 636Valeant Pharmaceuticals International (VRX) and GlaxoSmithKline plc (GSK) recently announced that the US Food and Drug Administration (FDA) issued a complete response letter (CRL) for the new drug application (NDA) for their epilepsy candidate, ezogabine. The regulatory body said that the CRL was...
-
Setback for Valeant Epilepsy Drug - Analyst Blog
Friday, December 3, 2010 - 7:00pm | 636Valeant Pharmaceuticals International (VRX) and GlaxoSmithKline plc (GSK) recently announced that the US Food and Drug Administration (FDA) issued a complete response letter (CRL) for the new drug application (NDA) for their epilepsy candidate, ezogabine. The regulatory body said that the CRL was...
-
Setback for Valeant Epilepsy Drug - Analyst Blog
Friday, December 3, 2010 - 6:28pm | 636Valeant Pharmaceuticals International (VRX) and GlaxoSmithKline plc (GSK) recently announced that the US Food and Drug Administration (FDA) issued a complete response letter (CRL) for the new drug application (NDA) for their epilepsy candidate, ezogabine. The regulatory body said that the CRL was...
-
Setback for Valeant Epilepsy Drug - Analyst Blog
Friday, December 3, 2010 - 6:28pm | 636Valeant Pharmaceuticals International (VRX) and GlaxoSmithKline plc (GSK) recently announced that the US Food and Drug Administration (FDA) issued a complete response letter (CRL) for the new drug application (NDA) for their epilepsy candidate, ezogabine. The regulatory body said that the CRL was...
-
An Update on Alexza Pharma (ALXA) - Analyst Blog
Friday, December 3, 2010 - 1:06pm | 1243Jason Napodano, CFA On October 10, 2010, the U.S. FDA issued a complete response letter (CRL) on the approval of AZ-004 (Staccato loxapine) for the rapid treatment of agitation in patients with schizophrenia or bipolar disorder. The FDA raised four issues in the CRL with the new drug...
-
An Update on Alexza Pharma (ALXA) - Analyst Blog
Friday, December 3, 2010 - 12:46pm | 1243Jason Napodano, CFA On October 10, 2010, the U.S. FDA issued a complete response letter (CRL) on the approval of AZ-004 (Staccato loxapine) for the rapid treatment of agitation in patients with schizophrenia or bipolar disorder. The FDA raised four issues in the CRL with the new drug...
-
Sequenom Underwriters Exercise Full Option of 2.1M Shares
Friday, December 3, 2010 - 9:02am | 71Sequenom, Inc. (Nasdaq: SQNM) today announced that the underwriters of its previously announced common stock offering that priced on December 2, 2010 have exercised in full an option to purchase an additional 2,100,000 shares of its common stock. Including the additional shares being purchased,...